We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos Receives €2 Million from Osteoarthritis Alliance with Servier
News

Galapagos Receives €2 Million from Osteoarthritis Alliance with Servier

Galapagos Receives €2 Million from Osteoarthritis Alliance with Servier
News

Galapagos Receives €2 Million from Osteoarthritis Alliance with Servier

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Receives €2 Million from Osteoarthritis Alliance with Servier"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced the receipt of €2 million for a partial milestone in the osteoarthritis alliance with Servier. This payment contributes to Group revenues in 2013.

"We continue to make progress in this alliance, which aims to develop innovative osteoarthritis therapies based on novel targets identified by Galapagos," said Onno van de Stolpe, CEO of Galapagos.

In July 2010, Servier and Galapagos announced their alliance to develop new oral medicines for the treatment of osteoarthritis.

Galapagos is responsible for the discovery and development of new candidate drugs against novel targets, and Servier has an exclusive option to license these after the completion of Phase 1 clinical trials.

Galapagos is eligible to receive up to €290 million in success-based milestones, plus royalties on commercial sales. Galapagos also retains exclusive US commercialization rights to all commercial compounds.

Advertisement